Avidity Biosciences, Inc.
RNADrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Mar 15, 2026
5wMarket Overview
Stock performance and market intelligence
3 upcoming, 0 past
AOC 1001 (del-desiran) Phase 3 Results Expected
Primary completion for AOC 1001 (del-desiran) trial (NCT06411288) in DM1
SourceAOC 1001 (del-desiran) Phase 3 Results Expected
Primary completion for AOC 1001 (del-desiran) trial (NCT06411288) in DM1
SourceAOC 1020 Phase 2 Results Expected
Primary completion for AOC 1020 trial (NCT05747924) in FSHD
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
AOC 1001 (del-desiran)
DM1
AOC-1020
Facioscapulohumeral Muscular Dystrophy
AOC 1044
Duchenne Muscular Dystrophy
AOC 1001
DM1
AOC 1020
FSHD
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
AOC 1001 (del-desiran) | Phase 3 | DM1 | - |
AOC-1020 | Phase 3 | Facioscapulohumeral Muscular Dystrophy | - |
AOC 1044 | Phase 2 | Duchenne Muscular Dystrophy | - |
AOC 1001 | Phase 2 | DM1 | - |
AOC 1020 | Phase 2 | FSHD | - |
Regulatory & News
Approvals, filings, and latest developments